CD4 and cancer: Parallel to this revival of interest in CD4+ T cells, there has also been significant research directed at producing a universal cancer vaccine based on promiscuous class II epitopes from self-molecules such as survivin [31–33] (an inhibitor of apoptosis) and telomerase reverse transcriptase (TERT) [34–36] (Table 1).